Company · TVTX
Travere Therapeutics, Inc.
Nasdaq's symbol directory lists TVTX on Nasdaq as “Travere Therapeutics, Inc. - Common Stock”.
In the 12 months to Nov 8, 2026: insiders sold on 19 occasions ($80.9M); 14 planned-sale notices; 5 filings by holders of 5% or more; 2 company reports (Form 8-K, since May 26, 2026).
All insider filings at the SEC · Appeared in No. 27, No. 26
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Dube Eric M, CHIEF EXECUTIVE OFFICER sold $38.5M
- Heerma Peter, EVP, CHIEF COMMERCIAL OFFICER sold $17.9M
- ROTE WILLIAM E., Chief Research Officer sold $13.1M
- Cline Christopher R., CHIEF FINANCIAL OFFICER sold $3.2M
- Inrig Jula, EVP, Head of R&D & CMO sold $2.8M
- Elizabeth E. Reed, Chief Legal Officer and GC sold $2.3M
- Meckler Jeffrey A sold $1.3M
- LYONS GARY A sold $633K
- Coughlin Timothy sold $501K
- Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER sold $335K
and 1 more people.
Every trade (19)
- SELLDube Eric M, CHIEF EXECUTIVE OFFICER sold $13.1M
- SELLDube Eric M, CHIEF EXECUTIVE OFFICER sold $7.0M
- SELLHeerma Peter, EVP, CHIEF COMMERCIAL OFFICER sold $539K
- SELLDube Eric M, CHIEF EXECUTIVE OFFICER sold $12.4M
- SELLHeerma Peter, EVP, CHIEF COMMERCIAL OFFICER sold $11.0M
- SELLROTE WILLIAM E., Chief Research Officer sold $7.1M
- SELLHeerma Peter, EVP, CHIEF COMMERCIAL OFFICER sold $6.4M
- SELLROTE WILLIAM E., Chief Research Officer sold $6.0M
- SELLDube Eric M, CHIEF EXECUTIVE OFFICER sold $6.0M
- SELLCline Christopher R., CHIEF FINANCIAL OFFICER sold $3.1M
- SELLInrig Jula, EVP, Head of R&D & CMO sold $2.8M
- SELLElizabeth E. Reed, Chief Legal Officer and GC sold $2.3M
- SELLCalvin Sandra, SVP, CHIEF ACCOUNTING OFFICER sold $335K
- SELLMeckler Jeffrey A sold $1.3M
- SELLCline Christopher R., CHIEF FINANCIAL OFFICER sold $43K
- SELLLYONS GARY A sold $317K
- SELLLYONS GARY A sold $316K
- SELLCoughlin Timothy sold $501K
- SELLBaynes Roy D. sold $225K
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- ERIC DUBE $13.0M
- ERIC DUBE $6.9M
- PETER HEERMA $526K
- ERIC DUBE $12.2M
- PETER HEERMA $10.8M
- WILLIAM ROTE $7.1M
- PETER HEERMA $6.7M
- WILLIAM ROTE $6.3M
- ERIC DUBE $6.3M
- CHRISTOPHER CLINE $3.3M
- JULA INRIG $2.9M
- ELIZABETH REED $2.6M
- SANDRA CALVIN $354K
- JEFFREY MECKLER $1.3M
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- FMR LLC 6.1%
- Armistice Capital, LLC 1.67%
- BANK OF AMERICA CORP /DE/ 5.8%
- STATE STREET CORPORATION 4.6%
- FMR LLC 7.7%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Nov 2, 2026
- Departure or appointment of directors or officers Sep 21, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.